189 related articles for article (PubMed ID: 37419078)
1. Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland -on behalf of the UK national coordinating committee for breast pathology.
Zaakouk M; Quinn C; Provenzano E; Boyd C; Callagy G; Elsheikh S; Flint J; Millican-Slater R; Gunavardhan A; Mir Y; Makhija P; Di Palma S; Pritchard S; Tanchel B; Rakha E; Atallah NM; Lee AHS; Pinder S; Shaaban AM
Breast; 2023 Aug; 70():82-91. PubMed ID: 37419078
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of a HER2-Low Focused IHC Scoring System with High Inter-Observer Concordance The Australian HER2-low Breast Cancer Concordance Study.
Farshid G; Armes J; Dessauvagie B; Gilhotra A; Kumar B; Mahajan H; Millar E; Pathmanathan N; Snell C
Mod Pathol; 2024 Jun; ():100535. PubMed ID: 38852812
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis.
Sun H; Kang EY; Chen H; Sweeney KJ; Suchko M; Wu Y; Wen J; Krishnamurthy S; Albarracin CT; Ding QQ; Foo WC; Sahin AA
Breast Cancer Res Treat; 2024 Jun; 205(2):403-411. PubMed ID: 38441847
[TBL] [Abstract][Full Text] [Related]
4. Concordance between pathologists and between specimen types in detection of HER2-low breast carcinoma by immunohistochemistry.
Wang J; Yoon E; Krishnamurthy S
Ann Diagn Pathol; 2024 Jun; 70():152288. PubMed ID: 38452457
[TBL] [Abstract][Full Text] [Related]
5. Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry.
Robbins CJ; Fernandez AI; Han G; Wong S; Harigopal M; Podoll M; Singh K; Ly A; Kuba MG; Wen H; Sanders MA; Brock J; Wei S; Fadare O; Hanley K; Jorns J; Snir OL; Yoon E; Rabe K; Soong TR; Reisenbichler ES; Rimm DL
Mod Pathol; 2023 Jan; 36(1):100032. PubMed ID: 36788069
[TBL] [Abstract][Full Text] [Related]
6. Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study.
Baez-Navarro X; van Bockstal MR; Nawawi D; Broeckx G; Colpaert C; Doebar SC; Hogenes MCH; Koop E; Lambein K; Peeters DJE; Sinke RHJA; Bastiaan van Brakel J; van der Starre-Gaal J; van der Vegt B; van de Vijver K; Vreuls CPH; Vreuls W; Westenend PJ; van Deurzen CHM
Mod Pathol; 2023 Jan; 36(1):100009. PubMed ID: 36788064
[TBL] [Abstract][Full Text] [Related]
7. "HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH" Answer to the statistical issue to avoid misinterpretation.
Casterá Redal C; Bernet Vegué L
Ann Diagn Pathol; 2020 Oct; 48():151566. PubMed ID: 32763505
[TBL] [Abstract][Full Text] [Related]
8. HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH.
Casterá C; Bernet L
Ann Diagn Pathol; 2020 Apr; 45():151451. PubMed ID: 31955049
[TBL] [Abstract][Full Text] [Related]
9. Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low-Expressing Breast Cancer Cohort.
Karakas C; Tyburski H; Turner BM; Wang X; Schiffhauer LM; Katerji H; Hicks DG; Zhang H
Am J Clin Pathol; 2023 May; 159(5):484-491. PubMed ID: 36856777
[TBL] [Abstract][Full Text] [Related]
10. Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study.
Buza N; Euscher ED; Matias-Guiu X; McHenry A; Oliva E; Ordulu Z; Parra-Herran C; Rottmann D; Turner BM; Wong S; Hui P
Mod Pathol; 2021 Jun; 34(6):1194-1202. PubMed ID: 33536574
[TBL] [Abstract][Full Text] [Related]
11. Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis.
Turashvili G; Leung S; Turbin D; Montgomery K; Gilks B; West R; Carrier M; Huntsman D; Aparicio S
BMC Cancer; 2009 May; 9():165. PubMed ID: 19476653
[TBL] [Abstract][Full Text] [Related]
12. Inter-observer agreement in reporting HER 2 Neu protein over expression by immunohistochemistry.
Al Haddabi I; Qureshi A; Saparamadu A; Al Hamdani A; Al Riyami M; Ganguly S
Indian J Pathol Microbiol; 2014; 57(2):201-4. PubMed ID: 24943750
[TBL] [Abstract][Full Text] [Related]
13. Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors.
Palm C; Connolly CE; Masser R; Padberg Sgier B; Karamitopoulou E; Simon Q; Bode B; Tinguely M
Diagnostics (Basel); 2023 Jan; 13(1):. PubMed ID: 36611460
[TBL] [Abstract][Full Text] [Related]
14. Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry.
Helin HO; Tuominen VJ; Ylinen O; Helin HJ; Isola J
Virchows Arch; 2016 Feb; 468(2):191-8. PubMed ID: 26493985
[TBL] [Abstract][Full Text] [Related]
15. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays.
Laurinaviciene A; Dasevicius D; Ostapenko V; Jarmalaite S; Lazutka J; Laurinavicius A
Diagn Pathol; 2011 Sep; 6():87. PubMed ID: 21943197
[TBL] [Abstract][Full Text] [Related]
16. HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens.
Tsuda H; Kurosumi M; Umemura S; Yamamoto S; Kobayashi T; Osamura RY
BMC Cancer; 2010 Oct; 10():534. PubMed ID: 20925963
[TBL] [Abstract][Full Text] [Related]
17. Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer.
Viale G; Basik M; Niikura N; Tokunaga E; Brucker S; Penault-Llorca F; Hayashi N; Sohn J; Teixeira de Sousa R; Brufsky AM; O'Brien CS; Schmitt F; Higgins G; Varghese D; James GD; Moh A; Livingston A; de Giorgio-Miller V
ESMO Open; 2023 Aug; 8(4):101615. PubMed ID: 37562195
[TBL] [Abstract][Full Text] [Related]
18. Improved concordance of challenging human epidermal growth factor receptor 2 dual in-situ hybridisation cases with the use of a digital image analysis algorithm in breast cancer.
Gough M; Liu C; Srinivasan B; Wilkinson L; Dunk L; Yang Y; Schreiber V; Tuffaha H; Kryza T; Hooper JD; Lakhani SR; Snell CE
Histopathology; 2023 Oct; 83(4):647-656. PubMed ID: 37366040
[TBL] [Abstract][Full Text] [Related]
19. Reading immunohistochemical slides on a computer monitor--a multisite performance study using 180 HER2-stained breast carcinomas.
Nassar A; Cohen C; Albitar M; Agersborg SS; Zhou W; Lynch KA; Heyman ER; Lange H; Siddiqui MT
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):212-7. PubMed ID: 21475038
[TBL] [Abstract][Full Text] [Related]
20. Inter-observer agreement among pathologists in grading the pathological response to neoadjuvant chemotherapy in breast cancer.
Yamaguchi T; Mukai H; Akiyama F; Arihiro K; Masuda S; Kurosumi M; Kodama Y; Horii R; Tsuda H
Breast Cancer; 2018 Jan; 25(1):118-125. PubMed ID: 28856554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
